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The thyroid hormone receptor ␣1 (TR␣) exhibits a dual role
as an activator or repressor of its target genes in response to
thyroid hormone (T3). Previously, we have shown that TR␣, formerly thought to reside solely in the nucleus bound to DNA,
actually shuttles rapidly between the nucleus and cytoplasm. An
important aspect of the shuttling activity of TR␣ is its ability to
exit the nucleus through the nuclear pore complex. TR␣ export
is not sensitive to treatment with the CRM1-specific inhibitor
leptomycin B (LMB) in heterokaryon assays, suggesting a role
for an export receptor other than CRM1. Here, we have used a
combined approach of in vivo fluorescence recovery after photobleaching experiments, in vitro permeabilized cell nuclear
export assays, and glutathione S-transferase pull-down assays to
investigate the export pathway used by TR␣. We show that, in
addition to shuttling in heterokaryons, TR␣ shuttles rapidly in an
unfused monokaryon system as well. Furthermore, our data show
that TR␣ directly interacts with calreticulin, and point to the
intriguing possibility that TR␣ follows a cooperative export pathway in which both calreticulin and CRM1 play a role in facilitating
efficient translocation of TR␣ from the nucleus to cytoplasm.

The thyroid hormone receptor ␣1 (TR␣)4 is a member of the
nuclear receptor superfamily of transcription factors. TR␣ acts
as an intracellular receptor for thyroid hormone (T3), thereby
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regulating expression of T3-responsive genes associated with
many aspects of development, growth, and metabolism.
Among the nuclear receptors, TR␣ is particularly intriguing in
that it can modulate transcription whether or not it is bound to
T3. Consistent with this dual role as an activator or repressor of
transcription, at steady state TR␣ appears to be almost exclusively localized in the nucleus. However, we have shown that
the receptor, in fact, shuttles rapidly between the nucleus and
cytoplasm (1). Whereas the significance of this nucleocytoplasmic shuttling remains to be precisely characterized, this activity
may be related directly to regulation of TR␣ target genes as well
as to yet unknown non-genomic functions (2).
Nucleocytoplasmic shuttling occurs as a result of a dynamic
balance between the recognition of nuclear localization signals
(NLS) and nuclear export signals (NES) by particular import
and export factors termed importins and exportins, respectively (3). Most nuclear receptors appear to enter the nucleus
via importin ␣/␤ recognition and subsequent translocation
through the nuclear pore complex (3, 4). Unlike nuclear import,
however, the export pathways followed by nuclear receptors
remain more elusive.
The most thoroughly studied and well characterized nuclear
export pathway involves the exportin CRM1. Many shuttling
transcription factors outside of the nuclear receptor superfamily follow a CRM1-dependent mechanism (5, 6). Like other
nuclear receptors, however, TR␣ lacks the leucine-rich NES
associated with classical CRM1-mediated nuclear export (1, 7).
Concordantly, we have shown through interspecies heterokaryon assays that TR␣ nuclear export is not inhibited by leptomycin B (LMB), a potent inhibitor of CRM1 activity. These
data clearly indicate that, at least in a heterokaryon system, TR␣
can use a CRM1-independent nuclear export pathway (1).
There is compelling evidence that suggests that the Ca2⫹binding protein calreticulin (CRT) may play a role in the
nuclear export of several nuclear receptors (8 –12). For example, the glucocorticoid receptor (GR) undergoes CRT-dependent nuclear export (11, 12) mediated through its highly conserved DNA binding domain (DBD) (8). However, the extent to
which CRT functions as an export receptor has remained a subject
of debate because its primary role is in the quality control of protein folding in the ER. In addition to this process, CRT has been
implicated in an increasing number of critical cellular processes
including regulation of Ca2⫹ homeostasis (13–15), integrin-mediated cell adhesion (16 –18), numerous roles in immune response
(19, 20), and cardiac muscle development (21–23).
As noted above, a widely used technique to study the subcellular trafficking of nuclear receptors has been the interspecies
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heterokaryon assay (1, 8, 24 –28). Recently, it has been reported
that the polyethylene glycol (PEG)-induced fusion of the cytoplasm during this assay disrupts the ER, thereby causing a transient elevation in cytosolic CRT levels as the protein is released
from the ER lumen (29). This fusion process may alter the
export kinetics of some shuttling proteins. For example, in contrast to the rapid shuttling of GR observed in heterokaryon
assays (8, 25), GR shuttling was found to occur only slowly over
a period of hours during fluorescence recovery after photobleaching (FRAP) experiments in monokaryons (29). Moreover, in contrast to heterokaryon fusion experiments in which
GR shuttling was shown to be CRT-dependent (8), slow GR
recovery in experiments other than heterokaryon fusions was
shown to occur in a CRT-independent manner (29). Given
these results, the question has arisen as to whether CRT-dependent nuclear export occurs under physiological conditions
or merely in response to exogenous environmental stresses
such as cell fusion.
With these data in mind we sought to ascertain whether TR␣
shuttles under physiological conditions and, if so, whether it
follows a CRT or CRM1-dependent nuclear export pathway. To
this end, we used a combined approach of in vivo FRAP experiments, in vitro digitonin-permeabilized cell nuclear export
assays, and GST pull-down assays. Taken together, our in vivo
and in vitro data point to the intriguing possibility that TR␣
uses an export pathway in which CRT binds directly to TR␣
and, thereby, promotes a cooperative interaction in which both
CRT and CRM1 play a role in mediating rapid, efficient translocation of TR␣ from the nucleus to cytoplasm.

EXPERIMENTAL PROCEDURES
Plasmids—The plasmid pGFP-TR␣ encodes a functional
GFP-TR␣ fusion protein expressed under human cytomegalovirus promoter control. This plasmid was constructed by subcloning the PCR product of rTR␣1 (rat) cDNA into the
enhanced GFP expression plasmid pEGFP-C1 (Clontech Laboratories, Inc.) using SacI and BamHI enzymes (1).
The plasmid pNES-GFP-GST-NLS was a gift from R. Haché
(University of Ottowa, Ottowa, Ontario) and contains the classic HIV-1 Rev NES sequence cloned into the ApaI site of pGFPGST-NLS, a plasmid that includes the sequence of the classic
simian virus 40 (SV40) large T antigen NLS at the 3⬘ end
(described further in Ref. 29). The plasmid pGEX-CRTwt was a
gift from B. Paschal and encodes full-length calreticulin subcloned into the pGEX-KG vector for overexpression in bacteria
(12). The plasmid pET-His-CRM1-H was a gift from J. Kjems
and encodes His-CRM1 for overexpression in bacteria (28).
Cell Culture—HeLa cells (ATCC CCL-2) were cultured in
MEM supplemented with 10% fetal bovine serum (Invitrogen)
containing penicillin (100 units/ml)/streptomycin (100 g/ml),
at 37 °C under 5% CO2 and 98% humidity. K41 (crt⫺/⫺) and K42
(crt⫹/⫹) cells were a generous gift from M. Michalak (30). These
mouse embryonic fibroblasts were cultured in Dulbecco’s modified Eagle’s medium with 10% calf serum under similar conditions. Cells were grown to 70 –90% confluency.
Transient Transfection and Live Cell Imaging—For transient
transfections, cells were seeded at 4 –7 ⫻ 105 cells per 60-mm
vented dish (Nunc, Rochester, NY) onto 5-cm coverslips.
SEPTEMBER 12, 2008 • VOLUME 283 • NUMBER 37

Twenty-four h after seeding, cells at 40 – 60% confluency were
transfected with 4 g of plasmid DNA and 20 l of Lipofectamine Reagent (Invitrogen) in Opti-MEM I Reduced Serum
Medium (Invitrogen) according to the manufacturer’s protocol. Reduced serum medium was replaced with complete
medium 16 –18 h post-transfection.
After transfection, cells were used for microscopy within
48 h. Prior to mounting in an enclosed perfusion chamber
(Bioptechs, Butler, PA), coverslips were incubated in 2 ml of
complete media containing 100 g/ml cycloheximide (Sigma),
penicillin (100 units/ml)/streptomycin (100 g/ml), and 2– 4
nM LMB (Sigma) or with vehicle (0.1% methanol) for 30 min.
Coverslips were then washed with 2 ml of Dulbecco’s phosphate-buffered saline (PBS) and mounted. For the duration of
each experiment, cells were incubated in MEM or Dulbecco’s
modified Eagle’s medium containing 50 g/ml cycloheximide,
penicillin (50 units/ml)/streptomycin (50 g/ml), and 2– 4 nM
LMB or vehicle (0.1% methanol).
Images were collected from an inverted Nikon ECLIPSE TE
2000-E fluorescence microscope equipped with a Radiance
2100 laser scanning unit using a ⫻60 1.2 NA water objective
(Nikon). The 488-nm line of a krypton-argon laser with a bandpass 515/30 nm emission filter was used for GFP detection and
images were obtained using the time course module of Laser
Sharp 2000 (Zeiss, Thornwood, NY).
FRAP was recorded to analyze shuttling of proteins between
nuclei within monokaryons. All FRAP experiments were performed in a temperature-controlled setting using a FCS2 livecell chamber heating system and objective heater system
(Bioptechs) to maintain 37 °C. After the appropriate temperature was reached, an initial image was recorded from an area
containing a multinucleated GFP-expressing cell using 2– 8%
laser power from the 488 nm line of a krypton-argon laser. One
nucleus within the monokaryon was exposed at 50% laser
power for two cycles using the same laser. After this bleaching
exposure, sequential images were taken every 5 min for 11
cycles. To minimize undesired photobleaching, low laser intensities of 2– 8% were again used for post-bleach images. For
quantitative analysis of digitized images, fluorescence intensity
values were generated using ImageJ (NIH). Bleached and
unbleached nuclei were each considered as independent
regions of interest. In addition, these values took into account
the background brightness levels during each experiment.
Intensity values were subsequently normalized so that the total
fluorescence within each monokaryon after bleaching was
equal to 1. Graphs were generated using Microsoft Excel.
Heterokaryon Assay—For the preparation of heterokaryons,
crt⫺/⫺ cells (K42) were seeded at 2–2.5 ⫻ 105 cells/well onto
coverslips in 6-well dishes. Cells were then transfected with a
GFP-TR␣ expression vector. Twenty-four hours post-transfection of the crt⫺/⫺ cells, human HeLa cells were trypsinized and
resuspended in heterokaryon growth medium containing 70%
Dulbecco’s modified Eagle’s medium, 10% fetal bovine serum,
and 20% sterile distilled water. The resuspended cells were then
plated on the same coverslips at 5– 6 ⫻ 105 cells/well. The cells
were then incubated for 2.5 h in the presence of cycloheximide
at 50 g/ml followed by 30 min in media with cycloheximide at
100 g/ml at 37 °C to allow adherence. Subsequently, the cells
JOURNAL OF BIOLOGICAL CHEMISTRY
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were rinsed with Dulbecco’s PBS. For cell fusion, coverslips
were placed on 100-l drops of warm 50% polyethylene glycol
1500 (Roche Applied Science, Indianapolis, IN) and incubated
for exactly 2 min. Each coverslip was then rinsed with Dulbecco’s PBS and incubated for 2 h at 37 °C in heterokaryon growth
media containing 100 g/ml cycloheximide.
Following incubation, the cells were rinsed with Dulbecco’s
PBS and then fixed for 10 min in 3.7% formaldehyde. After
three 5-min washes with Dulbecco’s PBS, the cells were permeabilized using 0.2% Triton X-100. Following three 5-min
washes with Dulbecco’s PBS the cells were incubated in 200 l
of 1.5% normal goat serum for 20 min. The cells were then
washed with Dulbecco’s PBS and incubated for an additional 20
min in 1.5% normal goat serum containing 0.5 units/ml rhodamine-phalloidin (Molecular Probes, Eugene, OR) to visualize
actin. Following a wash in Dulbecco’s PBS, the cells were then
incubated for 10 min in Dulbecco’s PBS containing 10 g/ml
Hoechst 33258 (Sigma) to visualize DNA. Finally, the coverslips
were mounted on slides using GelMount mounting media
(Biomeda, Foster City, CA). Slides were examined by fluorescence microscopy and images were obtained with a CoolSNAP
HQ2 CCD camera (Photometrics, Tucson, AZ) and NIS-Elements software (Nikon).
Antibody Staining—Cells were grown to 80 –90% confluency
and plated at 2 ⫻ 105 cells/well onto coverslips in six-well
dishes (Nunc). 24 h post-plating, coverslips were incubated in 2
nM LMB or 0.1% methanol for 5 h. The cells were then fixed and
permeabilized. After fixation and permeabilization, cells were
incubated in 1.5% normal goat serum in Dulbecco’s PBS for 30
min. The cells were then washed in Dulbecco’s PBS and probed
for 1 h in blocking solution containing rabbit polyclonal antiCRT antibodies (Stressgen, Ann Arbor, MI) diluted to 1:1000.
Cells were then washed in Dulbecco’s PBS three times for 5 min
each prior to incubation for 1 h with fluorescein isothiocyanateconjugated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA) diluted to 1:600. After incubation the cells were
washed in Dulbecco’s PBS and mounted using GelMount
containing 4⬘,6-diamidino-2⬘-phenylindole dihydrochloride
(Sigma) (0.5 g/ml). CRT staining was visualized by fluorescence microscopy.
Nuclear Extractions—Cells were plated at 1–2 ⫻ 107 and
grown for 24 h to confluence in 100-mm vented dishes. Cells
were rinsed 3 times in Dulbecco’s PBS and nuclei lysed in 1 ml
of Cell Lysis Solution (10 mM Hepes, pH 7.9, 10 mM KCl, 10 mM
EDTA pH 8.0, 0.4% IGEPAL (Sigma), 0.5 mM phenylmethylsulfonyl fluoride (Roche), 1 mM dithiothreitol (dithiothreitol)
(Omnipur, Gibbstown, NJ), Complete Mini EDTA-free Protease Inhibitor Mixture Tablet (1 tablet/10 ml) (Roche) for 10 min
at 4 °C. The lysed cells were scraped and sheared by four passages through a 21-gauge needle. The quality and purity of the
nuclei were monitored by differential interference contrast
(DIC) microscopy at ⫻600; shearing was repeated until ⬎95%
of nuclei were visibly free from ER and other cytoplasmic contamination. Nuclei were pelleted by a 5-s pulse spin (200 ⫻ g) at
4 °C in a microcentrifuge. The cytoplasmic fraction was collected and the purified nuclei were washed twice with 1 ml of
extraction solution. A small fraction of the resuspended nuclei
from the last wash was observed by DIC to confirm that the
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nuclei had remained intact and were free from ER and other
cytoplasmic debris. The nuclear proteins were then extracted
with 100 l of Nuclear Extraction Solution (20 mM Hepes, pH
7.9, 0.4 M NaCl, 10 mM EDTA, pH 8.0, 10% glycerol, 0.5 mM
phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, Complete
Mini EDTA-free Protease Inhibitor Mixture Tablets (1 tablet/10 ml)). Proteins from nuclear and cytoplasmic fractions
were then analyzed by Western blot.
Western Blotting—The approximate concentration of total
protein in nuclear and cytoplasmic samples was determined by
absorption at 280 nm. For cytoplasmic and whole cell extract,
40 g of protein were analyzed per lane, 40 – 60 g per lane
were used for nuclear extracts, and 0.5–2 l of rabbit reticulocyte lysate (RRL) (Promega, Madison, WI) were analyzed. The
samples were separated by 8% SDS-PAGE and transferred to
polyvinylidene difluoride membranes (Amersham Biosciences)
by semi-dry electroblotting (Bio-Rad). The membranes were
incubated overnight in the presence of blocking solution (Trisbuffered saline (TBS), 1% bovine serum albumin, 0.1% Tween
20). After six washes with TBS, the membranes were incubated
with the primary antibodies for 1 h. For the detection of CRT
and ␤-tubulin both rabbit polyclonal anti-CRT antibodies
(SPA-600D, Stressgen) and rabbit polyclonal anti-␤-tubulin
antibodies (Affinity Bioreagents, Golden, CO) were mixed
together in blocking solution at 1:20,000 and 1:200, respectively. For the detection of CRM1 and CRT, Western blots were
incubated separately with anti-CRM1 (Affinity Bioreagents) or
anti-CRT (Stressgen) antibodies at 1:200 or 1:20,000, respectively. The blots were then washed six times with TBS and incubated with a horseradish peroxidase-conjugated goat anti-rabbit IgG (GE Healthcare) at 1:30,000 for 1 h in blocking solution.
Following this incubation, the blots were washed again six
times and incubated with ECL-Plus detection reagent (GE
Healthcare). Subsequently, the blots were analyzed using a
Storm 860 Molecular Imager scanner (GE Healthcare) and
ImageJ (NIH).
Protein Overexpression—Plasmids coding for the protein of
interest were transformed into competent Escherichia coli
(BL21 DE3-RIl) (Stratagene, La Jolla, CA), per the manufacturer’s protocol, and grown to an A600 of 0.6 – 0.8 at 37 °C. Expression was induced with 0.5 mM isopropyl ␤-D-thiogalactoside
(Fisher Scientific, Pittsburgh, PA) and grown 3–5 h at 30 °C.
Post-expression cultures were centrifuged at 1,700 ⫻ g for 15
min at 4 °C; bacterial pellets were stored at ⫺80 °C prior to
protein purification.
GST Protein Purification—Bacterial pellets were resuspended in 10 ml of B-PER威 Bacterial Protein Extraction Reagent (Pierce), 1 ml of 5.0 mg/ml lysozyme (Fisher), 10 mM Tris,
pH 8.0, and one Complete Mini EDTA-free Protease Inhibitor
Mixture tablet (Roche). Resuspended pellets were incubated on
ice for 30 min. The pellets were subsequently sonicated (Sonic
Dismembrator model 100; Fisher) on ice to fully lyse the bacteria. The lysed mixture was then centrifuged at 17,950 ⫻ g for 15
min at 4 °C, and the supernatant was applied to 200 l of 50%
glutathione-Sepharose 4B resin (GE Healthcare). Samples were
incubated for 60 min at 4 °C with gentle rotation, then centrifuged for 5 min at 500 ⫻ g at 4 °C to pellet the resin. The resin
pellet was washed 3 times with 10 ml of ice-cold PBS (140 mM
VOLUME 283 • NUMBER 37 • SEPTEMBER 12, 2008
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NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.3)
and then transferred to a Microfilter Spin Column (Pierce) and
washed twice with 600 l of ice-cold PBS. 100 l of Glutathione
Elution Buffer (10 mM glutathione) was added to the column,
incubated at room temperature for 2– 4 min with agitation,
then centrifuged at 700 ⫻ g for 30 s at 4 °C to collect eluted
protein. The elution step was repeated 3 times. The eluted fractions were pooled and dialyzed (Slide-A-Lyser威 Mini Dialysis
Units, 7000 MWCO, Pierce) against Dulbecco’s PBS overnight
at 4 °C. Protein samples were then concentrated using Micron
Ultracel YM-30 Centrifugal Filter Devices (Millipore, Bedford,
MA). Concentrated protein samples were analyzed by SDSPAGE and protein concentration estimated using a NanoDrop威 ND-1000 full-spectrum UV-Visual Spectrophotometer.
Samples were stored at ⫺80 °C.
Permeabilized Cell Nuclear Export Assays—HeLa cells were
seeded on 22-mm Coverslips for Cell GrowthTM (Fisher) in
6-well culture dishes (Nunc) at a concentration of 2–3 ⫻ 105
cells per well. 24 h post-seeding each well was transiently transfected with 2 g of plasmid DNA and 10 l of Lipofectamine
reagent (Invitrogen) in Opti-MEM I reduced serum medium,
and incubated 12–16 h. After 12–16 h Opti-MEM I was
replaced with MEM containing 10% fetal bovine serum. After
4 h cells were washed 3 times with 2 ml/well of ice-cold export
buffer (20 mM Hepes, pH 7.3, 110 mM KOAc, 5 mM NaOAc, 2
mM Mg(OAc)2, 1 mM EGTA, 2 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, Complete Mini EDTA-free Protease
Inhibitor Mixture tablet (1 tablet/10 ml) (Roche), then permeabilized with digitonin (50 g/ml; Calbiochem, San Diego, CA)
in export buffer for 4.5 min. Subsequently, cells were rinsed
with 2 ml/well of ice-cold export buffer for 10 min. Coverslips
were then inverted over 50-l drops of export reaction mixture
(energy regeneration system composed of 5 mM creatine phosphate, 20 units/ml creatine phosphokinase, 0.5 mM ATP, 0.5
mM GTP, 5⫻ export buffer, 670 nM GST-CRT, and 25 l of
RRL) on parafilm in a moist chamber for 30 min at 30 °C. Cells
were then fixed in 3.7% formaldehyde (Fisher) for 10 min followed by a 5-min rinse with export buffer. Coverslips were subsequently mounted on slides with 8 l of GelMount with 4⬘,6diamidino-2⬘-phenylindole (0.5 g/ml), and viewed by
fluorescence microscopy.
GST Pull-down Assays—Pull-down assays using GST-CRT
were performed using the ProFound Pull-down GST Protein:
Protein Interaction Kit (Pierce), and modified amounts of GST
resin/protein. GST resin was equilibrated with five 0.5-ml
washes of TBS (25 mM Tris䡠HCl, 0.15 M NaCl, pH 7.2):ProFound Lysis Buffer (1:1). Bait protein immobilization was performed at 4 °C for 30 min with gentle rocking. For GST-CRT/
His-CRM1 interactions, 50 l of 50% GST resin was used to
bind 40 g of GST-CRT bait protein. For GST-CRT/His-TR␣
and GST-CRT/His-TR␣/His-CRM1 interactions, 5 l of 50%
GST resin was used to bind 4 and 7 g of GST-CRT bait protein, respectively. Bound bait protein was washed 5 times with
0.5 ml of TBS:ProFound Lysis Buffer (1:1). Prey protein capture
was performed at 4 °C for 1 h with gentle rocking. For GSTCRT:CRM1, GST-CRT:TR␣ binding, and GST-CRT:TR␣:
CRM1, 40 g of His-CRM1, 2 g of His-TR␣ (Active Motif,
Carlsbad CA), and 3.5 g of His-TR␣, 3.5 g of His-CRM1 prey
SEPTEMBER 12, 2008 • VOLUME 283 • NUMBER 37

were used. Bait-Prey elution was performed with 50 l of 100
mM Glutathione Elution Buffer for GST-CRT/CRM1 interactions, and 12.5 l for GST-CRT/TR␣ and GST-CRT/TR␣/
CRM1 interactions. All elutions were analyzed via SDS-PAGE
using an 8 –16% precast Gene Mate Express Gel (ISC BioExpress, Kaysville, UT). Gels were stained with SimplyBlueTM
SafeStain (Invitrogen) and imaged using a Bio-Rad Gel Doc XR
documentation system with Quantity One analysis software
(version 4.6.1).
Coimmunoprecipitation Assays—For coimmunoprecipitation assays, HeLa, crt⫺/⫺, and crt⫹/⫹ cells were transfected with
expression vectors for GFP-TR␣, or GFP alone as a control, in
100-mm plates using Lipofectamine 2000 (Invitrogen). 20 h
post-transfection, the medium was replaced with medium containing 2– 4 nM LMB or vehicle (0.1% methanol). Cells were
lysed 5 h later and nuclear extracts were prepared using a
Nuclear Extract Kit (Active Motif) according to the manufacturer’s instructions. Nuclear extracts were incubated with antiCRT antibodies bound to Dynal Dynabeads威 Protein G
(Invitrogen) for 2 h at 4 °C. The immunoprecipitated material
was captured on a DynaMagTM-2 magnetic particle concentrator, washed, and eluted in SDS-PAGE sample buffer. Samples of
immunosupernatants and immunoprecipitated material were
separated by 8% SDS-PAGE. Replicate Western blots were prepared and probed with anti-CRT, anti-CRM1, and anti-GFP
(Santa Cruz Biotechnology Inc.) antibodies, followed by chemiluminescent detection.

RESULTS
TR␣ Shuttling in Living Cells Is Leptomycin B Sensitive—The
thyroid hormone receptor is a dynamic protein that shuttles
rapidly between the nucleus and cytoplasm in heterokaryon
assays. This shuttling is not blocked by LMB in heterokaryons,
indicating that TR␣ is exiting the nucleus by a CRM1-independent pathway in the heterokaryon assay (1). The heterokaryon assay involves PEG-induced fusion of the cytosols of
transfected cells of one species (e.g. mouse) with untransfected
cells of another species (e.g. human). Movement of the protein
of interest can then be monitored from the nuclei of transfected
cells into the shared cytosol of the fused cells and, subsequently,
into the nuclei of the opposing species. The recent finding that
PEG-induced cell fusion causes changes in the cellular environment including a transient elevation in CRT levels (29) has
called into question the validity and interpretation of previous
heterokaryon experiments.
We first sought to determine whether TR␣ shuttles under
physiological conditions by performing experiments in living
cells, independent of heterokaryon formation. To maintain
physiological conditions, we used a FRAP assay in multinucleate live cells (monokaryons) to monitor the movement of GFPTR␣ from unbleached to bleached nuclei. Unlike in heterokaryons, a monokaryon system does not require cell fusion or other
manipulation that would compromise the integrity of the ER
and thus, presumably, maintains low levels of cytosolic CRT.
Transfected monokaryons were selected and one nucleus
within these cells was exposed to intense laser illumination.
This exposure resulted in loss of fluorescence within the
selected nucleus due to irreversible photobleaching of the GFP
JOURNAL OF BIOLOGICAL CHEMISTRY
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measured and compared with the
concomitant decrease in intensity
within unbleached nuclei. Through
image analysis and plotting of these
fluorescence intensity data, we were
able to determine the relative
degree of nucleocytoplasmic shuttling within particular cell types and
treatments. Specifically, we assayed
for TR␣ shuttling in human HeLa
and mouse crt⫹/⫹ cell lines, both of
which express CRT. We show that,
in contrast to the slow nuclear
export observed for GR in COS-7
cells (29), TR␣ in fact shuttles rapidly between nuclei in both HeLa
(Fig. 1A) and crt⫹/⫹ monokaryons
(Fig. 1B). These data are in close
agreement with those observed for
TR␣ shuttling kinetics in heterokaryons (1), and suggest that TR␣
may play an as yet unknown role in
cytosolic signaling pathways. After
confirming that TR␣ rapidly shuttles between nuclei in these cells, we
sought to determine whether TR␣
follows a CRM1 or CRT-dependent
nuclear export pathway in live,
unfused cells.
Based on our previous data showing that TR␣ nucleocytoplasmic
shuttling is not blocked by LMB in a
heterokaryon system (1), we predicted that we would observe rapid
shuttling of TR␣ between nuclei
when HeLa and crt⫹/⫹ monokaryons were treated with LMB. Surprisingly, we saw only slow recovery of
TR␣ within photobleached monokaryon nuclei of both cell types during FRAP experiments (Fig. 1). In
contrast to previous data for heterokaryons in which near complete
equilibration between nuclei was
seen over the course of 1 h (1),
recovery of fluorescence to
bleached nuclei within live monoFIGURE 1. TR␣ shuttling is inhibited by treatment with LMB in live monokaryons expressing CRT. A, HeLa
cells were transfected with a GFP-TR␣ expression plasmid and nucleocytoplasmic shuttling was monitored karyons treated with LMB was limthrough FRAP (n ⫽ 7). White arrowheads indicate photobleached nuclei. Parallel experiments were performed ited to only 22% (⫾3%) for HeLa
in the presence of LMB (n ⫽ 6) to block CRM1-mediated nuclear export and DIC images were taken to delineate cells and 14% (⫾2%) for crt⫹/⫹ cells
cell borders. Fluorescence recovery graphs indicating relative shuttling of GFP-TR␣ were generated. Black
squares indicate relative fluorescence levels within unbleached nuclei and open diamonds represent levels over a similar time course (Fig. 1).
within bleached nuclei. Any apparent change in nucleus morphology is a result of cell movement over the These results are in sharp contrast
course of the experiment. Error bars, ⫾ 1 S.E. B, as in A using crt⫹/⫹ cell line (n ⫽ 10, ⫺LMB; n ⫽ 6, ⫹LMB). Bar,
to parallel FRAP experiments per10 m.
formed in the absence of LMB, durfluorophore. The initial bleaching did not, however, result in ing which TR␣ shuttling was much more rapid. In these experloss of fluorescence to neighboring nuclei within the same cells iments recovery to the bleached nuclei was measured at 56%
(Fig. 1). A series of images was taken for each individual exper- (⫾4%) equilibration for HeLa cells and 88% (⫾2%) equilibraiment in which fluorescence recovery to bleached nuclei was tion for crt⫹/⫹ cells over 1 h (Fig. 1). To graphically illustrate the
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(1) creates an artificial environment
in which the effects of deactivating
CRM1 activity are overshadowed by
cell fusion-dependent up-regulation of alternative export factors
such as CRT. With this possibility in
mind, we sought to determine
whether CRT is used as an alternative, or cooperative, nuclear export
receptor by TR␣ in vivo.
TR␣ Shuttling Is Inhibited in
Living Cells Deficient in CRT
Expression—CRT has previously
been shown to function as an exportin for nuclear receptors related to
TR␣ (8, 11, 12, 31). To address the
question of whether TR␣ export is
also mediated by CRT, we transiently transfected mouse embry⫺/⫺
FIGURE 2. TR␣ requires CRT for nuclear export. crt
cells were transfected with a GFP-TR␣ expression onic fibroblast cells isolated from
plasmid and nucleocytoplasmic shuttling was monitored through FRAP (n ⫽ 8). White arrowheads indicate CRT knock-out mouse embryos
bleached nuclei. DIC images were taken to delineate cell borders and a fluorescence recovery graph indicating (crt⫺/⫺ cells) (23) with GFP-TR␣
relative shuttling of GFP-TR␣ was generated. Bar, 10 m.
and monitored FRAP in bleached
nuclei of transfected CRT-deficient
monokaryons (Fig. 2).
Prior to analysis of nuclear
export, we first assessed the ability
of TR␣ to enter the nucleus of
crt⫺/⫺ cells. Although nuclear
import of both the tumor suppressor p53 and the transcription factor
FIGURE 3. The CRM1-mediated nuclear export pathway is active in crtⴚ/ⴚ cells. An expression plasmid for NF-AT3 are impaired in cells defi⫺/⫺
a CRM1-dependent shuttling control protein (GFP-GST-NES-NLS) was transfected into crt
cells and nuclecient in CRT expression, other shutocytoplasmic shuttling was monitored by FRAP. White arrowheads represent bleached nuclei. Bar, 10 m.
tling proteins including GR and
sensitivity of TR␣ nucleocytoplasmic shuttling to LMB, mean GATA4 are unchanged in their import properties regardless of
brightness values for photobleached and unbleached nuclei whether CRT is present (32). Thus, the altered nuclear import
were plotted as a function of time post-bleach. Fluorescence of some proteins in crt⫺/⫺ cells is a specific effect and is not
intensity was normalized so that the overall fluorescence of indicative of a general defect in the import cycle. Nuclear
bleached and unbleached nuclei was equal to 1.0 (arbitrary import of TR␣ was not impaired in crt⫺/⫺ cells, indicating that
units). After normalization, convergence of the representative CRT is not required for its nuclear localization (Fig. 2).
curves for bleached nuclei and unbleached nuclei toward one
Although TR␣ remained localized to crt⫺/⫺ cell nuclei prior
another represents the degree of fluorescence equilibration to FRAP, we observed a striking reduction in its nucleocytobetween these compartments. When one bleached and one plasmic shuttling after photobleaching (Fig. 2). Indeed, only
unbleached nucleus are present, complete equilibration occurs 14% (⫾2%) fluorescence equilibration from unbleached nuclei
at 0.5 fluorescence units.
to bleached nuclei was seen in the crt⫺/⫺ cell line. In contrast,
To ensure that any recovery in GFP signal to bleached nuclei HeLa cells and crt⫹/⫹ cells not treated with LMB showed 56%
occurred as a result of nucleocytoplasmic shuttling and not as a (⫾4%) and 88% (⫾2%) fluorescence equilibration with
result of de novo protein synthesis, all experiments were per- unbleached nuclei, respectively (Fig. 1). To demonstrate that
formed in the presence of cycloheximide. DIC microscopy was the lack of CRT in these cells was not responsible for any nonalso performed to visualize monokaryon borders, thereby con- specific action preventing all nucleocytoplasmic shuttling,
firming that the experiments in which no shuttling was crt⫺/⫺ cells were also transfected with a shuttling control conobserved were conducted in cells that were, indeed, multinu- struct, pNES-GFP-GST-NLS. The fusion protein localizes to
cleated as opposed to adjacent independent cells.
the nucleus at steady state and shuttles via a CRM1-mediated
Taken together, these data show that TR␣ nuclear export is nuclear export pathway (29). As expected, shuttling of this proLMB-sensitive, suggesting that in live, unfused cells the CRM1 tein was not inhibited in crt⫺/⫺ cells, indicating that the CRM1
pathway plays a role in mediating export of TR␣. One possible pathway is functional in these cells (t1⁄2 ⬍ 10 min) (Fig. 3). Taken
explanation for these unexpected results is that the hetero- together, these data support the hypothesis that TR␣ can follow
karyon system used previously to assay for CRM1 dependence a CRT-mediated nuclear export pathway.
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population of CRT was localized to
the nuclei of the cells used in our
study, we isolated nuclei by biochemical fractionation. To ensure
that the nuclei extracted were free
of ER and other cytoplasmic contamination, during the purification
process nuclei were monitored by
DIC at high resolution (Fig. 4A).
Purification steps were repeated
until only nuclei that were free of ER
and other cytoplasmic debris
remained. Proteins were extracted
from the cytoplasmic fraction and
from the purified nuclei and analyzed by Western blot. Blots were
probed simultaneously with antiCRT and anti-␤ tubulin, which was
used to normalize the data. When
comparing the amount of CRT in
purified nuclei to the amount of
tubulin, a strictly cytoplasmic protein, we found that the purified
nuclei from HeLa cells were significantly enriched in CRT (p ⬍ 0.001)
(Fig. 4, B and C). In HeLa cells, the
ratio between CRT and tubulin
increased from 1.7 ⫾ 0.3 in the cytoplasm to 9.6 ⫾ 4.2 in the nucleus
indicating that the amount of CRT
observed in the purified nuclei is not
a result of residual cytoplasmic contamination. These results were also
significant in crt⫹/⫹ cells (p ⬍
0.001) (Fig. 4, B and C). In these
cells, the ratio between CRT and
tubulin increased from 1.3 ⫾ 0.1 in
the cytoplasm to 2.3 ⫾ 0.7 in the
purified nuclei. Together these data
provide further evidence that CRT
is present in a small but significant
fraction within the nucleus in the
cell lines used for our experiments.
FIGURE 4. CRT is localized to the cytosol and nuclei of various cell types. A, to ensure that purified nuclei To further demonstrate that CRT is
were free of ER and other cytoplasmic contaminants, nuclear fractions were monitored by DIC. Left panel, a localized to multiple cellular comclump of nuclei with residual ER and cytoplasmic debris; these nuclei were subjected to additional purification
steps prior to use (see “Experimental Procedures”). Right panel, an isolated nucleus free of residual ER and other partments, we performed indirect
cytoplasmic contaminants. B, proteins extracted from purified nuclei and cytosolic fractions from HeLa and immunofluocrt⫹/⫹ cells were analyzed by Western blot, using anti-CRT and anti-␤ tubulin antibodies. Magic Marker (MM)
rescence assays. Consistent with the
size standard is indicated and crt⫺/⫺ cells were used as a negative control. A representative blot for HeLa cells
is shown. C, the ratio of CRT to tubulin increased significantly from cytosolic to nuclear fractions in both HeLa Western blot analysis a small popucells (n ⫽ 12, *, p ⬍ 0.001) and crt⫹/⫹ cells (n ⫽ 13, **, p ⬍ 0.001). Error bars, 99.9% confidence interval. D, HeLa lation of nuclear CRT was observed
cells incubated for 5 h in the presence or absence of LMB, as indicated, were fixed and labeled with anti-CRT
in addition to a more prominent
antibodies by indirect immunofluorescence. Bar, 10 m.
cytoplasmic pool (Fig. 4D).
TR␣ nuclear export is partially inhibited by treatment with
CRT Is Localized to the Cytoplasm and Nuclei of Various Cell
Types—Previously, CRT was believed to reside solely in the ER. LMB (Fig. 1). This suggests a role for CRM1 in TR␣ shuttling, in
Recently, however, increasing numbers of reports have identi- addition to that played by CRT, and points to a possible interfied small fractions of CRT in both the cytosolic and nuclear play between CRT and CRM1. A direct interaction between
compartments of various cell lines in addition to its primary CRT and CRM1 could, in theory, induce a shift in CRT toward
location within the ER (33–35). To assess whether a detectable the nucleus upon treatment with LMB, which would be indic-
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ative of CRM1 sequestering CRT in this compartment. To test
this, we treated cells with LMB and performed immunostaining
for CRT in situ. This treatment did not, however, induce a
detectable shift in the subcellular localization of CRT toward
the nucleus (Fig. 4D); a comparable population of nuclear CRT
was observed in both LMB-treated and untreated cells.

Polyethylene Glycol-induced Heterokaryon Formation
Restores TR␣ Export from CRT-deficient Cell Nuclei—Having
shown that TR␣ nuclear export is impaired in crt⫺/⫺ cells (Fig.
2), we sought to test whether TR␣ export could be restored by
the addition of exogenous CRT. To do so, we transfected crt⫺/⫺
cells with GFP-TR␣ and then fused them with untransfected
HeLa cells. Because PEG-induced heterokaryon formation
causes a transient elevation in cellular CRT levels (29), we
hypothesized that if TR␣ uses CRT for nuclear export that the
fusion process with CRT-expressing HeLa cells would restore
export in crt⫺/⫺ cells. This could occur either as a result of CRT
release from the HeLa cell ER or, alternatively, from the relatively low CRT levels present within HeLa cell nuclei and
cytosol prior to fusion. Experiments were performed in the
presence of cycloheximide to inhibit de novo protein synthesis.
Consistent with our prediction, we found that TR␣ was capable
of exporting from crt⫺/⫺ nuclei into the shared cytosol and
subsequently reimporting into HeLa nuclei in these heterokaryon assays (Fig. 5). Taken together, the results from these
FIGURE 5. Addition of CRT to CRT-deficient cells restores rapid nucleocytoplasmic shuttling and promotes export of thyroid hormone receptor heterokaryon experiments and our live-cell FRAP experiments
(TR␣) from CRT-deficient cell nuclei. crt⫺/⫺ cells were transfected with a support the hypothesis that TR␣ uses CRT as a nuclear export
GFP-TR␣ expression plasmid. Subsequently, CRT-expressing HeLa cells were
receptor.
plated on the same coverslip and cytoplasmic fusion was performed using
Efficient Nuclear Export of TR␣ in Permeabilized Cells
50% PEG. Left panel, cells were fixed and GFP-TR␣ localization was observed
by fluorescence microscopy. Nuclei of crt⫺/⫺ cells are indicated by white Requires Cytosol and CRT—To provide further evidence for a
arrowheads. Right panel, HeLa cell nuclei exhibit diffuse Hoechst staining,
whereas crt⫺/⫺ have a speckled appearance. Heterokaryon borders are visu- role of CRT in the nuclear export of TR␣, we performed peralized by staining of F-actin with rhodamine-phalloidin. Bar, 10 m.
meabilized cell in vitro nuclear export assays utilizing purified
recombinant GST-CRT. For this
assay, HeLa cells were transiently
transfected with a GFP-TR␣ expression plasmid. GFP-TR␣ displays a
complete and strong nuclear fluorescence 16 h post-transfection. At
this point the outer cell membrane
was permeabilized with digitonin
and export reactions were performed. First, we sought to assess
whether exogenous CRT was sufficient to induce nuclear export of
TR␣. Our results showed no observable change in TR␣ nuclear localization between 0 and 40 min irrespective of varying CRT concentration
from 270 nM to 1 M. During this
period, all TR␣ remained localized
to the nucleus (Fig. 6A).
To determine whether additional
factors were required to either permit nuclear import of CRT or to aid
in the nuclear export of TR␣ in conjunction with CRT, export reactions
containing CRT and a cytosol mixFIGURE 6. Nuclear export of thyroid hormone receptor (TR␣) in permeabilized cells. A, GFP-TR␣ remains ture (RRL) alone or a combination
nuclear at t40 in the presence of 670 nM CRT. HeLa cells transfected with a GFP-TR␣ expression plasmid were of CRT and RRL were similarly
digitonin permeabilized, and incubated in an export reaction containing CRT, energy regeneration system, and
assayed at 0 and 40 min. RRL is comexport buffer alone. At t40 no GFP-TR␣ export was observed. B, export reactions containing RRL, energy regeneration system, and export buffer were able to support ⬎80% loss of nuclear fluorescence of GFP-TR␣ at t40. monly used as a source of cytosol for
C, export reactions containing both CRT and RRL were able to support ⬎95% loss of nuclear fluorescence of nuclear import and export assays
GFP-TR␣ at t40. White values were normalized to 2,000 using IPlab 3.55 for A–C. D, enlarged section from panels
B, t40 (*), and C, t40 (**). White values for * from panel B and ** from panel C were adjusted to 200 for low intensity (36). Initially, we tested RRL alone.
visualization of the residual GFP-TR␣ in export reactions. Bar, 10 m.
As expected, at t0 TR␣ was localized
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FIGURE 7. RRL contains CRM1 but not CRT. HeLa whole cell extract and
varying volumes of RRL were subject to Western blot analysis, using antiCRM1 and anti-CRT antibodies. Magic Marker (MM) size standard is indicated.

to the nucleus. At t40 a moderate level of export was observed as
indicated by a decrease in GFP-TR␣ fluorescence in the nuclei
compared with t0 (⬎80% loss of fluorescence) (Fig. 6, B and D).
Upon addition of RRL and CRT in combination, however, we
observed a striking increase in the nuclear export of TR␣ as
compared with that which was observed for RRL or CRT individually. Indeed, over a similar time course nuclear export was
nearly complete (⬎95% fluorescence loss) (Fig. 6, C and D).
These data suggest that an additional factor (or factors) present
in the cytosol interacts cooperatively with CRT to mediate efficient nuclear export of TR␣.
The GTPase Ran plays an integral role in the shuttling of
many transcription factors and exists predominantly in a GTPbound state within the nucleus. In this conformation, RanGTP
participates in the formation of export complexes containing
the classical leucine-rich NES (3, 4, 37, 38). In addition, it also
stabilizes protein kinase inhibitor/CRT interactions as well as
enhances CRT-dependent nuclear export of protein kinase
inhibitor in permeabilized cells (12). It has been shown in permeabilized cell nuclear export assays that residual nuclear
RanGTP remaining in cells after permeabilization was sufficient to permit CRT-dependent nuclear export (12). To determine the role of Ran in the nuclear export of TR␣, we performed assays with recombinant CRT in the absence of
RanGTP or having supplemented the system with 1.9 M
RanGTP. We did not, however, observe any difference in TR␣
nuclear localization between these conditions; TR␣ remained
localized to the nucleus in either case (data not shown). This
suggests that RanGTP is not the limiting factor for TR␣ nuclear
export.
Several factors may play a role in stabilizing CRT/cargo interactions, inducing a conformational shift in CRT, or in other
nonspecific functions. Calcium, for example, modulates CRT
conformation within the lumen of the ER (39) and also regulates CRT function as a chaperone for the T-cell protein perforin (40). In addition, Ca2⫹ enhances CRT-mediated nuclear
export of GR-GFP but, interestingly, excess Ca2⫹ also inhibits
classical NES-regulated nuclear export of Rev-GFP in vitro (15).
We supplemented permeabilized cell export assays with 20 mM
Ca2⫹ in the presence of CRT but observed no difference in TR␣
nuclear localization. Under these conditions TR␣ remained
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localized to the nucleus (data not shown). These results suggest
that Ca2⫹ also is not the limiting factor required for nuclear
export in these assays.
Based on our findings in live cells that the nuclear export of
TR␣ shows partial CRM1 dependence (Fig. 1), we performed
Western blot analysis to test whether CRM1 was present in RRL
and could be the additional factor required for efficient CRTdependent nuclear export. Our data show that CRM1 was present in RRL and HeLa cell extracts, whereas CRT was detected
only in HeLa cell extract and was absent from RRL (Fig. 7).
These findings point to the possibility that CRM1 could be the
additional factor accounting for the enhanced export of TR␣ in
in vitro export assays supplemented with RRL. A cooperative
interaction between CRT and CRM1, whether direct or indirect, also accounts for the observation that TR␣ is not exported
as efficiently from nuclei treated with RRL, as CRT is absent
from this exogenous cytosol replacement.
TR␣ Interacts Directly with CRT—To determine whether
interactions between TR␣, CRT, and CRM1 during nuclear
export are direct or indirect, GST pull-down assays were performed (Fig. 8). A GST-CRT fusion protein was incubated with
His-tagged TR␣ (Fig. 8A), His-tagged CRM1 (Fig. 8B), or both
(Fig. 8C), and the input (flow-through) and binding (elution)
fractions were analyzed by SDS-PAGE. TR␣ interacted with
GST-CRT (Fig. 8A, lane 3), but not with GST alone (Fig. 8A,
lane 5). In contrast, all input CRM1 was present in the flowthrough fraction (Fig. 8B, lane 5); no CRM1 bound specifically
to CRT alone (Fig. 8B, lane 6), or together with TR␣ (Fig. 8C,
lane 4). Supplementing in vitro binding assays with RRL had no
effect on complex formation (data not shown). Complex formation in HeLa, crt⫹/⫹, and crt⫺/⫺ cells was not detectable by
coimmunoprecipitation assays (data not shown), suggesting
that interaction of TR␣ with CRT in situ is transient and that
only a small fraction of TR␣ forms export complexes at any
given time. This is consistent with the primarily nuclear population of TR at steady state.

DISCUSSION
Here, we present findings that provide evidence for a previously uncharacterized mechanism for the dynamic shuttling of
TR␣. We have used a combination of in vivo FRAP experiments, in vitro digitonin-permeabilized cell nuclear export
assays of transiently transfected cells, and GST pull-down
assays to investigate aspects of TR␣ subcellular trafficking.
Taken together, our data suggest a novel export mechanism in
which CRT directly binds TR␣, and CRT and CRM1 work
cooperatively to promote rapid, efficient export of TR␣ from
the nucleus (Fig. 9). Alternatively, when the CRM1 pathway is
blocked or CRT levels are increased under cellular stress, CRT can
act independently as a less efficient exportin. crt⫺/⫺ cell lines fail to
support nuclear export of TR␣, suggesting that CRT is indispensable for TR␣ nuclear export. Thus, CRT may be the most important component of the TR␣ nuclear export pathway. These data
suggest that CRT deficiency prevents CRM1 interacting either
directly or indirectly with TR␣, and inhibits both cooperative and
autonomous TR␣ export as a consequence.
Prior to this study, the role that CRT plays in nuclear export
was a subject of debate. Previously, CRT was thought to reside
VOLUME 283 • NUMBER 37 • SEPTEMBER 12, 2008
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FIGURE 9. Model for nuclear export of thyroid hormone receptor (TR␣)
involving a cooperative CRT and CRM1-mediated pathway. A, nuclear
export complex in cells expressing CRT (HeLa, crt⫹/⫹) in which CRT binding
promotes a cooperative export pathway involving CRM1. This cooperative
interaction is indicated by the double-headed curved arrow. CRM1 binding to
TR␣ may require additional factors (indicated by dashed line). Although CRT
levels are low under these conditions, export of TR␣ is efficient and rapid
export is observed. B, inefficient nuclear export of TR␣ in cells expressing CRT
(HeLa, crt⫹/⫹) occurs upon treatment with LMB. CRM1 is inactivated but CRT
can still support modest export autonomously. C, rapid export of TR␣ occurs
even in the presence of LMB upon PEG-induced heterokaryon fusion.
Although the CRM1 pathway is inactivated, transient CRT release from the ER
renders sufficient CRT levels to support rapid export of TR␣. D, crt⫺/⫺ cells do
not support nuclear export of TR␣ because CRT is not present to facilitate the
CRM1-dependent component of the export pathway.

permanently within the ER lumen where it participates in the
maturation of newly synthesized proteins and sequesters Ca2⫹.
In addition to its prominence in the ER, however, increasing
numbers of reports have suggested that CRT may in fact be
present in small fractions in other cellular compartments. For
example, CRT appears to interact with a ubiquitin-like nuclear
protein in the nucleus of rice cells (34). Moreover, CRT also
localizes to the nuclear matrix of some carcinoma cells and
assists in chromatin formation (35). All of these data suggest
that CRT is likely to possess an evolutionarily conserved ability
to access the nucleus, where it appears to serve multiple functions. Recently, a mechanism involving the post-translational

FIGURE 8. Thyroid hormone receptor (TR␣) interacts directly with CRT. In
vitro binding interactions were examined by GST pull-down assays. A, His-TR␣
(46 kDa) was retained by GST-CRT bait (lane 3, elution), whereas the negative
control GST-only bait did not retain TR␣ (lane 5, elution). Lane 1, Bio-Rad
prestained Kaleidoscope protein molecular mass standards, given in kDa
(P-KPS); lanes 2 and 4, TR␣ protein inputs; lanes 6 – 8, reference protein samples. B, CRM1 alone was not retained on either GST-CRT (lane 3, elution) or
negative control GST-only bait (lane 6, elution). Lane 1, Bio-Rad Kaleidoscope
protein molecular mass standards, given in kDa (KPS); lanes 2 and 5, His-CRM1
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flow-through (input); lane 4, no prey input, GST-CRT bait elution; lanes 7–9,
reference protein samples. C, TR␣ binds CRT, but His-CRM1 does not interact
directly with the TR␣-CRT complex. His-TR␣ was retained by GST-CRT bait
from the combined TR␣:His-CRM1 input, whereas the His-CRM1 was not
retained (lane 4, elution). The negative control GST-only bait did not retain
either TR␣ or His-CRM1 (lane 7, elution). Lane 1, Bio-Rad prestained Kaleidoscope protein molecular mass standards, given in kDa (P-KPS); lanes 2 and 5,
His-tagged TR␣ and CRM1 input; lanes 3 and 6, post-prey binding wash samples; lanes 8 –10, reference protein samples. The His-CRM1 input included
full-length CRM1 and lower molecular weight degradation products, as
indicated.
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processing and retrotranslocation of CRT from the ER to the
cytoplasm has been identified, suggesting a potential pathway
for CRT to subsequently gain access to the nucleus via import
(41).
Although low levels of CRT are found in multiple cellular
compartments, the majority of CRT present in heterokaryons
immediately after cell fusion comes as a result of ER disruption
and its release from the ER lumen (29). Although TR␣ export
was inhibited in crt⫺/⫺ monokaryons, rapid shuttling and fluorescence equilibration was observed between nuclei of heterokaryons. For CRT to mediate export of TR␣ from crt⫺/⫺ nuclei,
presumably it must first be imported into these same nuclei.
Following import, CRT could then interact with TR␣ and facilitate its nuclear export. Our in vitro nuclear export assays suggest that whereas CRT is necessary for efficient export, there is
also an additional factor (or factors) in the cytosol required for
its nuclear import, its role in the export of TR␣, or both. Based
on our in vivo FRAP experiments, our in vitro nuclear export
assays, and our Western blot analysis of RRL composition, we
suggest that at least one of these additional factors is the exportin CRM1.
In both HeLa and crt⫹/⫹ cell lines, TR␣ displayed rapid
nucleocytoplasmic shuttling in the absence of LMB. Although
the precise mechanism by which this export occurs remains to
be determined, there are several potential explanations. CRT
and CRM1 could undergo a conformational shift that maximizes interaction with components of the nuclear pore complex, thus expediting the export process. Alternatively, CRM1
could increase the affinity of CRT for TR␣ allowing for more
efficient export. In any case, the fluorescence equilibration
between photobleached and unbleached nuclei in monokaryons of either cell type (HeLa t1⁄2 ⫽ 40 min, crt⫹/⫹ t1⁄2 ⫽ 10 min)
indicates that TR␣ shuttles rapidly under these conditions.
As treatment with LMB results in covalent modification of a
critical cysteine residue within CRM1 (42), this potential cooperative interaction with CRT may be abolished upon LMB
treatment. As such, CRT may still be capable of binding TR␣
and facilitating export, albeit to a lesser extent. This would
explain our results in which TR␣ shuttling in HeLa and crt⫹/⫹
monokaryons occurs only slowly after treatment with LMB.
Finally, our model takes into account the cell fusion-dependent release of CRT during heterokaryon experiments (29) and
explains the stark contrast between LMB-insensitive TR␣ shuttling in heterokaryons (1) versus LMB-sensitive shuttling in
monokaryons (present study). Although CRT may be the limiting factor in TR␣ nuclear export under normal circumstances,
this limitation is countered by the increased efficiency of export
resulting from the cooperative pathway involving CRM1 (Fig.
9). Although CRM1 is undoubtedly inactivated by LMB treatment in heterokaryons, the attenuated nucleocytoplasmic
shuttling expected may not be observed due to the increased
cytosolic levels of CRT resulting from PEG-induced cell fusion.
Under these conditions, the relatively low levels of CRT found
within the nucleus or cytosol under normal circumstances
would be markedly increased and its low levels would no longer
be limiting. Although, according to this model, autonomous
CRT-mediated export of TR␣ is not as efficient as cooperative
export in the presence of CRM1, the sheer increase in free CRT
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directly after cell fusion may be enough to overcome this deficiency and allow rapid nuclear export to proceed in the presence of LMB (Fig. 9).
Previously, the only support for the hypothesis that CRT
mediates export of TR was the finding that the DBD of TR␤ is
sufficient to confer nuclear export when fused to a GFP
reporter. The DBDs of TR␤ and GR share 43% sequence homology and, most importantly, the amino acids predicted to be key
for CRT binding are conserved (12). Thus, it is not unreasonable to propose that the TR␤ DBD could also interact directly
with CRT, as has been shown for the GR DBD (8). Examining
the specific nucleocytoplasmic shuttling properties of TR␣
domains within CRT-deficient and CRT-expressing cell lines
will provide valuable insight into the physical basis for TR␣
binding of CRT. Comprehensive analysis of the effects of mutations by in vitro binding assays and in vivo functional assays
should help to identify and clarify those specific amino acid
sequences required for nuclear export, as well as nuclear
import, of TR␣.
In a prior study we showed that in vitro-generated 35S-labeled TR␣ does not interact with purified CRM1 in a His pulldown assay (28). However, most CRM1-dependent NESs bind
CRM1 with low affinity and often require additional adapter
proteins to serve as a bridge between CRM1 and the cargo protein being exported (3, 43). For example, Ran-binding protein 3
(RanBP3) directly binds CRM1 in the nucleus and increases the
affinity of CRM1 for NES containing cargo as well as RanGTP
(44, 45). In addition, RanBP3 binding also maximizes the interaction of the CRM1 export complex with nucleoporins of the
nuclear pore complex (44). Similar conditions are observed for
CRM1 binding of other regulatory proteins that participate in
nucleocytoplasmic shuttling. Although steroid receptor coactivator-1 contains two clusters of hydrophobic amino acids similar to the classic leucine-rich NES associated with CRM1-mediated nuclear export, this protein failed to accumulate within
the nuclei of COS-7 cells when these regions were mutated even
though its export was sensitive to LMB (46). Presumably then,
an unknown adapter protein that is recognized by both CRM1
and steroid receptor coactivator-1 accounts for the nuclear
accumulation of steroid receptor coactivator-1 upon LMB
treatment. Other examples include both the 60 S and 40 S
ribosomal subunits of the yeast Saccharomyces cerevisiae.
These large complexes undergo CRM1-mediated nuclear
export in an adapter-dependent manner (47– 49). Such situations are analogous to our TR␣ export pathway model in
which additional export factors may be required to facilitate
the CRM1-dependent component of TR␣ translocation
from the nucleus to cytoplasm.
The model presented here explains several previously anomalous observations relating to CRT, CRM1, and nuclear receptor export in general. There is certainly a discrepancy between
the shuttling kinetics of nuclear receptors in a heterokaryon
system versus under other experimental conditions, such as
those reported in Walther et al. (29). Particularly striking is the
disparity observed between protein shuttling within in vivo
monokaryon experiments compared with the interspecies heterokaryon assay. Here, for the first time, the observation that
some nuclear receptors such as TR␣ (present study) and GR
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(50, 51) rely in part on CRM1-dependent nuclear export can be
reconciled with the observation that cell lines deficient in CRT
expression, but retaining their CRM1 activity, fail to support
nuclear export of the same proteins (8) (present study).
Interestingly, we have also shown that the p53 tumor suppressor protein displays highly reduced shuttling kinetics in
crt⫹/⫹ monokaryons as compared with heterokaryon assays
using HeLa and NIH/3T3 cells.5 Although the significance of
these observations remain to be determined, they again highlight the complexity of nucleocytoplasmic transport pathways
and point to a similar discrepancy between p53 shuttling under
in vitro and in vivo conditions. As p53 undergoes nuclear export
in a CRM1-dependent manner (52–55), this observation
should be considered when designing experiments that attempt
to utilize p53 as a control for CRM1 activity.
These data provide insight into the nuclear export pathway
of TR␣ and suggest a possible mechanism by which other shuttling proteins may use complex and, to some extent, functionally redundant export modes involving both characterized
pathways (CRM1) and a multitude of other chaperones. In
addition, these results also represent a novel role in nuclear
export for the functionally diverse protein CRT. Although more
research will be necessary to precisely determine the significance of this cooperative export pathway, regulation of TR␣
target genes may be influenced in several ways. Inefficient TR␣
nuclear export in the absence of CRT could, for example, be
indicative of an evolved compensatory mechanism to up-regulate the transcription of genes involved in similar cellular processes as the numerous ones that have been identified for CRT.
Conversely, rapid shuttling of TR␣ dependent on an intact
cooperative export pathway may be representative of a general
mechanism to clear shuttling transcription factors from the
nucleus under physiological conditions. This cooperative
CRM1/CRT-mediated nuclear export pathway may be relevant
to related members of the nuclear receptor superfamily other
than TR␣. Identification of this export pathway and other
mechanisms by which nuclear receptors exit the nucleus will
contribute substantially to understanding the regulatory activity of these proteins. One challenge for the future will be to
examine how regulation of this cellular compartmentalization
is impaired or altered in the case of aberrant nuclear receptor
expression. In addition, defining how nuclear export integrates
TR␣ activity with other signaling pathways may provide important clues as to the mode of action of mutant TRs that are
responsible for a host of pathological conditions including cancer (56 –58).
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